Drug Trial Radar · NCT06641414
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Jan 22, 2025
Primary completion
Jun 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
Conditions
- Higher-risk Myelodysplastic Syndrome
Interventions
Lisaftoclax (APG-2575)Drug
QD, oral administration.
Azacitidine InjectionDrug
QD, hypodermic or intravenous injection.
PlaceboOther
QD, oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival(OS)Time frame: Up to 5 years
Locations
155 sites in 18 countries. Site status is shown where the registry gives one.
Ascentage Investigative Site
Birmingham, Alabama · Not yet recruiting
Ascentage Investigative Site
Phoenix, Arizona · Recruiting
Ascentage Investigative Site
Los Angeles, California · Recruiting
Ascentage Investigative Site
Sacramento, California · Recruiting
Ascentage Investigative Site
San Diego, California · Recruiting
Ascentage Investigative Site
Aurora, Colorado · Recruiting
Ascentage Investigative Site
Jacksonville, Florida · Recruiting
Ascentage Investigative Site
Chicago, Illinois · Recruiting
Ascentage Investigative Site
Indianapolis, Indiana · Recruiting
Ascentage
Iowa City, Iowa · Not yet recruiting
Ascentage Investigative Site
Louisville, Kentucky · Recruiting
Ascentage Investigative Site
Baltimore, Maryland · Recruiting
Ascentage Investigative Site
Minneapolis, Minnesota · Recruiting
Ascentage Investigative Site
Rochester, Minnesota · Recruiting
Ascentage Investigative Site
St Louis, Missouri · Recruiting
Ascentage Investigative Site
Lincoln, Nebraska · Recruiting
Ascentage Investigative Site
Hackensack, New Jersey · Recruiting
Ascentage Investigative Site
New York, New York · Recruiting
Ascentage Investigative Site
Rochester, New York · Recruiting
Ascentage Investigative Site
The Bronx, New York · Recruiting
Ascentage Investigative Site
Charlotte, North Carolina · Recruiting
Ascentage Investigative Site
Durham, North Carolina · Recruiting
Ascentage Investigative Site
Winston-Salem, North Carolina · Recruiting
Ascentage Investigative Site
Cleveland, Ohio · Recruiting
Ascentage Investigative Site
Columbus, Ohio · Recruiting
Ascentage Investigative Site
Eugene, Oregon · Recruiting
Ascentage Investigative Site
Pittsburgh, Pennsylvania · Recruiting
Ascentage Investigative Site
Providence, Rhode Island · Not yet recruiting
Ascentage Investigative Site
Austin, Texas · Recruiting
Ascentage Investigative Site
Houston, Texas · Recruiting
Ascentage Investigative Site
Tyler, Texas · Recruiting
Ascentage Investigative Site
Charlottesville, Virginia · Recruiting
Ascentage Investigative Site
Manassas, Virginia · Recruiting
Ascentage Investigative Site
Norfolk, Virginia · Recruiting
Ascentage Investigative Site
Edmonds, Washington · Recruiting
Ascentage Investigative Site
Issaquah, Washington · Recruiting
Ascentage Investigative Site
Seattle, Washington · Recruiting
Ascentage Investigative Site
Seattle, Washington · Recruiting
Ascentage Investigative Site
Milwaukee, Wisconsin · Recruiting
Ascentage Investigative Site
Waukesha, Wisconsin · Recruiting
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.